Board of Directors

Paul Truex

Paul F. Truex is currently Executive Chairman of Anthera Pharmaceuticals and served as President and CEO between 2004-2016. He was responsible for negotiating Anthera's multiple product licenses from Eli Lilly and Amgen and led Anthera's successful Initial Public Offering in 2010. Prior to founding Anthera Pharmaceuticals, Mr. Truex served as a Founder, Director, President and CEO of Peninsula Pharmaceuticals where Mr. Truex raised over $81 million of institutional capital (including $21 million from a strategic partner) and negotiated both of Peninsula's product agreements with Shionogi & Co., Ltd. and Takeda Chemical Industries. Peninsula was acquired by Johnson and Johnson in April of 2005 for $245 million in an all-cash transaction. The remaining entity, Cerexa was subsequently acquired by Forrest Laboratories for $480 million in cash.


During his career, Mr. Truex has been involved in life science transactions of over US$3 billion including Initial Public Offerings, M&A, in-licensing, out-licensing and venture financing. This includes over $300 million in venture capital investments and more than $800 million in various public equity and debt offerings including Anthera's Initial Public Offering in 2010 and Versicor's IPO in 2000. Prior to Peninsula, Mr. Truex was Vice President of Commercial Development for Vicuron (Acquired by Pfizer, NASDAQ: MICU) where he directed early commercial efforts for their infectious disease portfolio. Prior to joining Versicor, Mr. Truex worked at Eli Lilly and Company where he was involved and led various business development transactions including Lilly's joint venture with Icos for the development of Cialis®, (NASDAQ: ICOS) and out-licensing of Eraxis® to Vicuron. Mr. Truex held escalating roles in marketing and sales and was involved in the launch of three different products for the primary care physician market.


Mr. Truex obtained his Masters of Business Administration in Marketing and Finance from Indiana University and a Bachelor of Arts degree in Economics from the University of Waterloo. Mr. Truex is currently a Director of CymaBay Therapeutics (NASDAQ: CBAY), Anthera Pharmaceuticals (NASDAQ: ANTH), Feldan Therapeutics (Private), Gladius Pharmaceuticals (Private) and LQT Therapeutics (Private). His past board appointments include Peninsula Pharmaceuticals, Trius Therapeutics (NASDAQ: TSRX), Eiger Pharmaceuticals (NASDAQ: EIGR), and Protagonist Therapeutics (NASDAQ: PTGX). He joined Milestone's Board of Directors in 2012 and was Chairman of the Board from 2012 until 2016. Mr. Truex is also a member of the Indiana University West Coast Advisory Board for the Johnson Center of Entrepreneurship and Innovation.

Nathalie Chauret

Nathalie Chauret has over the 25 years of experience in the pharmaceutical industry where she has held various positions of increasing responsibility in Research and Drug Development. She is currently Senior Director, Drug Development at Bellus Health Inc. Prior to this position, she was Senior Director at Vertex Pharmaceuticals (2009-2017), Director at Virochem Pharma (2005-2009) and Research Fellow at Merck Frosst Canada (1991-2005). She has led strategies and headed several cross functional and global teams whose work resulted in the development of clinical and new medicines in the area of anti-infectious and anti-inflammatory diseases.


Her education consists of a Master degree in Chemistry from Université de Montréal. She has communicated and published over 50 manuscripts patents and presentations in the area of drug metabolism, discovery and drug development and was guest lecturer for the faculty of Medicine of the Université de Montréal

Vikas Goyal

Vikas joined SR One in 2011 after interning since 2009 with a background in corporate strategy and business development. Vikas was a consultant in McKinsey and Co's pharmaceutical practice, worked with dozens of start-ups and early stage companies as a consultant at Extera Partners, and worked in business development at Infinity Pharmaceuticals. He is a Kauffman Fellow (Class 17) and an active mentor for MassBio's MassConnect program.


Vikas received his B.A. in Neurobiology from Harvard University, and his MBA in Health Care Management from The Wharton School of Business, University of Pennsylvania.

Daniel Hétu, MD

With over 20 years of investment banking, corporate development, and licensing and investment experience, Daniel has been involved with life sciences companies at all stages of development in North America and overseas. With demonstrated success managing complex initiatives, projects and transactions, Daniel is recognized for his strategic thinking and problem-solving skills.


Daniel's investment activities are focused on building companies in the therapeutics and medical device sectors that develop products and technologies with a direct and significant impact on patient care. He manages Lumira Ventures' Montreal office.


An experienced senior executive with leading expertise in financing and corporate business development, Daniel located in Montréal spent 10 years at Shire Pharmaceuticals and at Biochem Pharma prior to its acquisition by Shire. As vice president, business development (North America) and vice president, corporate development, respectively, he led several financing, licensing and M&A transactions in the therapeutics, vaccine and diagnostics sectors. At Biochem, as well as serving on the company's portfolio committee and the steering committee of strategic research collaborations, Daniel served on the boards of investee companies. Prior to joining Biochem Pharma, Daniel was an investment banker at a major Canadian Investment Bank where he was involved in M&A and financing transactions across various industrial sectors.

Larry Sutton, MD, PhD

Larry Sutton is Gladius' Scientific Founder and serves as its Chief Scientific Officer. He has 35 years of research and clinical practice experience. He served on faculty at the University of Iowa and the University of Arkansas for Medical Sciences. While at the University of Iowa he co-invented along with Dr. Ronald Jones a rapid β-lactamase diagnostic that was out licensed and marketed as Cefinase PlusTM. During his tenure in Arkansas he also worked as the Director of Clinical Microbiology at the McClellan Memorial Veterans Hospital. He is currently on faculty at Benedictine College and Miami University. He has authored over 40 patents, scientific publications, book chapters, and proceedings. He graduated from the Medical Scientist Training Program at the University of Iowa where he earned his M.D. and Ph.D. in physical organic chemistry. He completed specialty training in Clinical Pathology at the University of Iowa and in Primary Care at Broadlawns Medical Center in Des Moines, Iowa.